URGES CMS TO ABANDON NATIONAL COVERAGE
ANALYSIS PROCESS FOR CANCER DRUGS
(March 14, 2003)
March 14, 2003
Thomas A. Scully
Centers for Medicare and Medicaid Services
200 Independence Avenue, S.W.
Hubert Humphrey Building - Room 433-G
Washington, D.C. 20201
Dear Mr. Scully:
The Cancer Leadership Council (CLC), representing cancer patients, providers,
and research institutions, is submitting these comments in response to
the initiation of a National Coverage Analysis of oxaliplatin. We understand
that this review process was commenced by the Centers for Medicare and
Medicaid Services on February 12, 2003, with an expected completion date
of May 13, 2003.
In the attached letter,
dated December 16, 2002, the CLC outlined its objections to the coverage
policy announced by the agency in the preamble to the Hospital Outpatient
Prospective Payment System, 67 Federal Register 66755-56 (Nov. 1, 2002).
It is the position of the CLC that the new CMS coverage policy is inconsistent
with the Medicare statute, which defines "drugs" to include
"any drugs or biologicals used in an anticancer chemotherapeutic
regimen for a medically indicated indication," including "any
use which has been approved by the Food and Drug Administration."
42 U.S.C. §1395(t)(2)(A and B).
We urge the agency
to abandon its efforts to conduct a National Coverage Analysis of all
new cancer drugs, as these efforts are inconsistent with the Medicare
Cancer Leadership Council
Alliance for Lung
American Cancer Society
American Society of Clinical Oncology
Association of American Cancer Institutes
Cancer Care, Inc.
Cancer Research and Prevention Foundation
The Children's Cause, Inc.
Coalition of National Cancer Cooperative Groups, Inc.
Colorectal Cancer Network
International Myeloma Foundation
The Leukemia & Lymphoma Society
Lymphoma Research Foundation
Multiple Myeloma Research Foundation
National Coalition for Cancer Survivorship
National Patient Advocate Foundation
North American Brain Tumor Coalition
Pancreatic Cancer Action Network (PanCAN)
US TOO! International, Inc.
The Wellness Community
Y-ME National Breast Cancer Organization
Enclosure - December 16, 2002, letter to Thomas A. Scully
cc: The Honorable
Tommy Thompson, Secretary, HHS
Mark McClellan, Commissioner, FDA
The Honorable Charles Grassley
The Honorable Max Baucus
The Honorable Deborah Pryce
The Honorable William Thomas
The Honorable Charles Rangel
The Honorable Nancy Johnson
The Honorable Pete Stark
The Honorable Billy Tauzin
The Honorable John Dingell
The Honorable Michael Bilirakis
The Honorable Sherrod Brown
Alex Azar, General Counsel, DHHS
Sheree Kanner, Associate General Counsel,
Health Care Financing Division, DHHS
Troy Daniel, Chief Counsel, FDA
to Medicare Payment Index
CLC | What's New |
Policy Issues |
Home | Sitemap
| Contact Info
© 2001-2002 Cancer Leadership Council. All rights reserved.
Please send comments and suggestions to email@example.com.